MiR-375- and miR-1 controlled coxsackievirus B3 do not have pancreatic or cardiotoxicity, but they have strong antitumor efficacy in colorectal cancer.

Incorporating tissue-specific miR-TS into the CVB3 genome using infectious cDNA constructs addresses the safety and efficacy issues of CVB3 strains by preventing replication in non-tumor tissues, enhancing safety and maintaining antitumor activity in colorectal cancer treatment.

JP7863899B2Active Publication Date: 2026-05-22TECH UNIV BERLIN
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
TECH UNIV BERLIN
Filing Date
2021-08-04
Publication Date
2026-05-22

AI Technical Summary

Technical Problem

Existing oncolytic coxsackievirus B3 (CVB3) strains cause adverse effects such as pancreatitis and myocarditis due to off-target replication in non-tumor tissues, limiting their safety and efficacy in cancer treatment.

Method used

Incorporation of tissue-specific microRNA target sequences (miR-TS) into the 5' and 3' untranslated regions of the CVB3 genome, using infectious cDNA constructs to prevent viral replication in pancreatic and cardiac tissues while maintaining antitumor activity.

Benefits of technology

The approach significantly reduces off-target replication in pancreas and heart, ensuring safety and maintaining effective antitumor efficacy in colorectal cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007863899000012
    Figure 0007863899000012
  • Figure 0007863899000013
    Figure 0007863899000013
  • Figure 0007863899000014
    Figure 0007863899000014
Patent Text Reader

Abstract

The present invention relates to an infectious complementary DNA (cDNA) construct comprising a cDNA of the CVB3 genomic RNA sequence of Coxsackievirus B3 (CVB3) and at least one or more microRNA target sequences (miR-TS) complementary to one or more microRNAs with tissue-specific expression patterns, wherein the at least one or more miR-TSs are integrated immediately adjacent to the 5'UTR and / or 3'UTR of the CVB3 protein-coding sequence.
Need to check novelty before this filing date? Find Prior Art